CRNX vs XERS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CRNX and XERS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CRNX and XERS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Crinetics Pharmaceuticals is a San Diego-based biopharmaceutical company that discovers and develops oral small-molecule therapies for endocrine diseases and endocrine-related tumors. Its first marketed product, PALSONIFY (paltusotine), is a non-peptide, once-daily oral selective somatostatin receptor ligand approved by the FDA in September 2025 and by European regulators in 2026 for acromegaly, a condition long treated with monthly injectable drugs. Behind PALSONIFY sits a deep pipeline of 10-plus programs, led by atumelnant (in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome) and CRN09682, a drug conjugate aimed at neuroendocrine tumors, plus earlier programs across Graves' disease, hyperparathyroidism, polycystic kidney disease, and other endocrine indications.

Full CRNX guide

Xeris Biopharma Holdings is a Chicago-based biopharmaceutical company that sells three approved medicines in the US. Recorlev (levoketoconazole) is a cortisol synthesis inhibitor for adults with endogenous hypercortisolemia, the hormonal condition behind Cushing's syndrome. Gvoke is a ready-to-use liquid glucagon, sold as a prefilled syringe and autoinjector (HypoPen), for severe low blood sugar in people with diabetes. Keveyis (dichlorphenamide) treats primary periodic paralysis, a rare muscle disorder. Two of the three came from the 2021 Strongbridge Biopharma acquisition, and the company also owns a formulation platform (XeriSol and XeriJect) that turns drugs into stable, non-aqueous injectables, which underpins its pipeline candidate XP-8121, a once-weekly subcutaneous levothyroxine for hypothyroidism.

Full XERS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CRNX drivers: Vertex acquisition completed at $85 cash; PALSONIFY launch, now inside Vertex.
• XERS drivers: Recorlev demand in an underdiagnosed disease; Margin expansion and operating leverage.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: With the merger closed, the deal-break risk that dominated the stock through the summer is gone, and former CRNX holders no longer carry any Crinetics-specific risk once they have received the $85.00 cash payment. For XERS, concentration is the central risk.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CRNX if you believe its drivers more; XERS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CRNX and XERS guides.

CRNX. Before the July 2026 announcement, Crinetics carried a market capitalization of roughly $4.5 billion despite minimal revenue, a valuation typical of a rare-disease biotech pricing in an early launch and pipeline optionality. Vertex's $85.00 cash offer, about $10 billion in equity value, set the final price, and the stock closed at $84.95 on its last trading day before the September 1, 2026 closing. Standard earnings multiples were never meaningful here, and with the shares delisted there is no live valuation left to measure.

XERS. At about $2.0B in market value and roughly $2.1B to $2.2B in enterprise value, XERS trades near 6x trailing revenue and about 5.5x the midpoint of 2026 guidance. The trailing P/E is not meaningful because the June quarter included a ~$31M non-cash charge from the convertible note exchange, which pushed reported results to a loss. Investors are effectively valuing the company on revenue growth and EBITDA trajectory, with Recorlev doing most of the work, and treating XP-8121 as an option whose value depends on a Phase 3 readout expected around late 2028.

Headline figures (approximate, October 2026): CRNX shows acquisition price (vertex, cash, paid sep 1, 2026) $85.00/share, deal equity value ~$10B, last close before delisting (aug 31, 2026) ~$84.95, revenue (q2 2026) ~$25.1M; XERS shows revenue (ttm) ~$335M (June 2026 quarter ~$92.1M, +29% YoY), 2026 revenue guidance ~$385M to $390M (+32% to +34%), adjusted ebitda (h1 2026) ~$34.4M (FY2025 ~$59.4M), gross margin (q2 2026) ~86%.

CRNX and XERS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CRNX and XERS exposure against your real portfolio. It is not an investment adviser.